Bioengineered Heart Muscle Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bioengineered heart muscle from human pluripotent stem cells are inefficient due to the disassociation of tissue and extracellular environment, leading to cell death and variable results across different cell lines, and often produce cardiomyocytes that are not functional when isolated.
Innovation Solution
A serum-free differentiation protocol using BMP4, Activin A, FGF2, and a GSK3-inhibitor, followed by Wnt-signaling pathway inhibition and mechanical stimulation, to directly differentiate pluripotent stem cells into bioengineered myocardium that retains developmental memory and exhibits spontaneous beating activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If tissue disassociation is performed to isolate cardiomyocytes, then cell isolation is achieved, but cell death increases and tissue memory is lost
Solution Approach 1:
The invention extracts only the necessary cardiomyocytes from the tissue while preserving the extracellular matrix and structural integrity. This is achieved by selectively isolating cardiomyocytes through controlled enzymatic digestion that spares the ECM, thereby maintaining tissue memory and reducing cell death compared to complete tissue disassociation
Solution Approach 2:
The invention performs preliminary preservation of the extracellular matrix and tissue architecture before cell isolation. By pre-establishing a supportive ECM framework and maintaining tissue structural cues prior to cardiomyocyte extraction, the method prevents loss of tissue memory and reduces mechanical stress-induced cell death during subsequent isolation steps
2Manufacturing precision
If tissue disassociation is performed to obtain isolated cardiomyocytes, then cell purity is improved, but developmental information is destroyed
Solution Approach 1:
The invention segments the tissue into isolated cardiomyocytes while preserving the extracellular matrix as a separate but connected component. This segmentation allows获得 pure cardiomyocytes for experimental use while the retained ECM maintains developmental cues and tissue memory, solving the contradiction between cell purity and information preservation
Solution Approach 2:
The extracellular matrix serves as an intermediary that bridges isolated cardiomyocytes and the original tissue architecture. By preserving the ECM as a mediator that contains embedded developmental information and structural cues, the invention enables pure cardiomyocyte isolation while maintaining access to tissue memory through the ECM intermediary
3Reliability
If disassociation steps are eliminated for direct differentiation, then cell death is reduced, but tissue functionality may be compromised
Solution Approach 1:
The invention performs preliminary establishment of a functional extracellular matrix framework before differentiating pluripotent stem cells into cardiomyocytes. This pre-formed ECM provides immediate structural support and developmental cues, enabling direct differentiation without disassociation steps while ensuring the resulting tissue achieves proper functional organization
Solution Approach 2:
The invention enables the differentiating cell population to self-organize into functional tissue structures by providing appropriate ECM cues and growth factors. The cells autonomously form contractile units and electrical coupling networks without requiring mechanical disassociation or external manipulation, thereby maintaining both high survival rates and proper tissue functionality
4Productivity
If protocol is modified for different hPSC lines, then line-specific efficiency is improved, but protocol complexity increases
Solution Approach 1:
The invention develops a universal differentiation protocol that functions across multiple hPSC lines by identifying and utilizing common developmental pathways and responsive signaling mechanisms. The protocol uses a standardized combination of growth factors and ECM components that universally trigger cardiomyocyte differentiation regardless of the specific hPSC line, thereby achieving both high productivity and protocol simplicity
Data Source
Figure 1A
Figure 1B~1G
Figure 1H~1N
AI summary
The present invention is directed to a method for producing bioengineered heart muscle (BHM) from pluripotent stem cells, generally comprising the steps of inducing mesoderm differentiation, cardiac differentiation, and cardiac maturation by directed tissue formation. The method is a robust, serum-free and reproducible way to produce BHM for multiple applications, and is applicable to multiple pluripotent stem cell lines. The present invention is also directed to the BHM produced by the method disclosed herein, as well as to uses of said BHM in pharmacologic and toxicity screenings, and its use in medicine.